Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn clinical trials, adults taking tirzepatide lost an average of around 20–21% of their body weight over 72 weeks at the highest dose. That is the headline figure, and it is real. But whether it is a reasonable expectation for you depends on a range of factors that no single statistic captures — and a prescriber, not a number, should help you set targets. Tirzepatide (sold in the UK as Mounjaro) is a prescription-only medicine that requires individual clinical assessment before it can be supplied; the average from the SURMOUNT-1 trial, published in the New England Journal of Medicine, is a starting point for a conversation, not a guarantee.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear regularly is some version of: "I've only lost X kg, am I failing?" It is an understandable worry, and it usually rests on a misconception worth clearing up gently: there is no universal target you are measured against on tirzepatide. The 20–21% average from SURMOUNT-1 is an average across thousands of participants, which means roughly half of those people lost less than that figure and half lost more. Averages hide a wide distribution.
What actually shapes your result includes your starting weight, metabolic health, how closely you follow dietary and activity changes alongside the medicine, how your body tolerates and responds to each dose, and how long you stay on treatment. Factors that influence weight loss on tirzepatide are worth understanding before you set expectations based on a headline percentage.
The prescriber's job is to help you find a dose that is both tolerable and effective for you, and to review progress at each stage. A number from a trial is background knowledge, not a personal prescription.
Tirzepatide is a prescription-only medicine in the UK, which means the only legal route to it is through a prescriber who has assessed you clinically. That clinical step has a cost, whether it is billed visibly or quietly folded into a headline figure.
Since Eli Lilly revised its UK list price in September 2025, the list price of the highest-dose pen rose to around £330; typical private prices across providers have ranged roughly £149–£375 per month depending on dose and supplier, as widely reported. Those headline figures sometimes exclude the consultation fee, the prescription charge, delivery, or the aftercare support you will want if side effects appear or you have questions mid-cycle. A low headline number can reflect a low dose, a missing service component, or both.
Understanding how Mounjaro is priced in the UK private market makes it easier to compare what is actually on offer rather than comparing single numbers that may not be measuring the same thing.
For a prescription medicine, price is the wrong test on its own. The right questions are: was I assessed by a qualified prescriber? Is this genuine medicine from the licensed UK supply chain? Will someone be available if I have a concern?
The MHRA has issued clear public warnings about counterfeit pens sold online, including fake tirzepatide seized from an unlicensed manufacturing site in the UK in 2025. Pens sold at prices far below the market rate, or without a clinical assessment, are a red flag, not a bargain. You can verify any online pharmacy on the GPhC register; nume's registration number is 9012878.
We are not the cheapest option in the market. That is a deliberate choice. One price at nume covers the consultation, the prescription, the medicine, next-working-day tracked delivery, and seven-day aftercare, no add-ons, no auto-renewals, no unpleasant surprises when you reorder. You can read more about our clinical team and how oversight works on our prescribers page.
SURMOUNT-1 reported around 20–21% average body-weight reduction at the 15mg maintenance dose over 72 weeks, among adults without diabetes. At lower doses, the average is lower; individual responses vary considerably. If you are starting out and wondering how much weight you should lose on the 5mg dose of Mounjaro, that page covers what to expect at that early stage in more detail.
It is also worth knowing that results at week 12 are not the same as results at week 72. Early progress tends to be faster; rate of loss usually slows as the body adjusts. If you want a clearer sense of how much weight you will lose on tirzepatide overall, that page breaks down the realistic range across different stages of treatment, and if you are curious about how much you should lose each week on Mounjaro, that page explains what a typical weekly rate looks like and why it shifts over time.
The short version: expect meaningful weight loss with tirzepatide when used consistently alongside lifestyle changes, assessed and supported by a prescriber. The exact number is personal, and if you want a fuller picture of how much weight you should lose on Mounjaro across the course of treatment, that page brings together the key factors that shape your individual outcome. The free consultation at nume is where that personal picture starts to form.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.